Knee Arthroscopy
Conditions
Keywords
Post-operative pain, Knee arthroscopy, Gabapentin, Etoricoxib, Elective ambulatory knee arthroscopy
Brief summary
To determine that when administered as part of a multimodal analgesic regimen, use of the new COX-2 antagonist etoricoxib (120 mg/day, per os) is more effective in improving postoperative pain management after knee arthroscopy than gabapentin (1.2 g/day, per os).
Detailed description
Background: Post-discharge pain remains a significant problem after many ambulatory surgery procedures. Both etoricoxib and gabapentin have been used to prevent postoperative pain; however their relative efficacy in the post-discharge period is not known. We hypothesized that daily use of etoricoxib would offer advantages over gabapentin as part of a multimodal analgesic regimen in the perioperative period due to its pharmacokinetic profile. Methods: Seventy-five healthy outpatients undergoing elective ambulatory knee arthroscopy were randomly assigned to receive identical-appearing capsules containing either a placebo, gabapentin (1.2g, or etoricoxib 120 mg, 30-90 min before skin incision and at 08H00 on the first, second, and third postoperative days. Post-discharge pain was treated with rescue dipyrone syrup (500 mg). Pain intensity (as assessed using a 100 visual analog scale), dipyrone usage, and the incidence of nausea and vomiting, sedation and anxiety were recorded at specific time intervals in the postoperative period. The recovery of functional activity was assessed at 96 h after surgery using a validated questionnaire.
Interventions
Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
Sponsors
Study design
Eligibility
Inclusion criteria
* Elective ambulatory knee arthroscopy
Exclusion criteria
* History of clinically-significant cardiovascular,pulmonary,hepatic,renal, neurologic, psychiatric or metabolic disease * Patients chronically receiving pain killers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Pain intensity (as assessed using a 100 visual analog scale) 2)Incidence of dipyrone usage | 96 hours post-operation |
Secondary
| Measure | Time frame |
|---|---|
| The recovery of functional activity | 96 hours |
Countries
Israel